{
    "sponsor_name": "",
    "study_acronym": "",
    "tested_imp": "",
    "comparative_drug": "",
    "study_type": "",
    "interventional_study_phase": "",
    "study_design": "",
    "aim_of_study": "",
    "target_disease": "",
    "type_of_randomization": "",
    "randomization_stratification": [],
    "apixaban_dosing": "",
    "dalteparin_dosing": "",
    "apixaban_supply_form": "",
    "dalteparin_supply_form": "",
    "scheduled_visits": [],
    "primary_efficacy_outcome": "",
    "secondary_efficacy_outcomes": [
        "The individual components of the primary efficacy outcome",
        "Symptomatic recurrence of VTE",
        "All-cause death",
        "The composite of the primary efficacy outcome plus major bleeding",
        "Any major cardiovascular event",
        "All venous thromboembolic events",
        "Quality of Life (QoL) assessed by the Anti-Clot Treatment Scale (ACTS)"
    ],
    "primary_safety_outcome": "",
    "secondary_safety_outcomes": [
        "Clinically Relevant Non-Major Bleeding (CRNMB)",
        "Composite of major bleeding and CRNMB",
        "Permanent early discontinuation of the study drug due to safety reasons"
    ],
    "maximum_sample_size_per_arm": 0,
    "recommended_inclusion_criteria": [],
    "recommended_exclusion_criteria": []
}